Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 1.00 |
| ▸ | AR | P10275 | 1/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 2/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18181214 | 0.85 | EGFR (1.00) | EGFRARPIK3CDPIK3CAIMPDH2 | |
| SCHEMBL24783500 | 0.81 | EGFR (0.69) | EGFRARPIK3CDPIK3CAFGFR4 | |
| SCHEMBL28041954 | 0.81 | EGFR (0.69) | EGFRARPIK3CDPIK3CAFGFR4 | |
| SCHEMBL16368637 | 0.81 | EGFR (0.68) | EGFRARPIK3CDPIK3CAFGFR4 | |
| SCHEMBL21646348 | 0.81 | EGFR (0.68) | EGFRARPIK3CDPIK3CAFGFR4 | |
| SCHEMBL23055235 | 0.81 | EGFR (0.68) | EGFRARPIK3CDPIK3CAFGFR4 | |
| SCHEMBL2998449 | 0.81 | EGFR (0.68) | EGFRARPIK3CDPIK3CAFGFR4 | |
| SCHEMBL24782968 | 0.81 | EGFR (0.68) | EGFRARPIK3CDPIK3CAFGFR4 | |
| Hydrochloric Acid SCHEMBL25267663 | 0.80 | EGFR (0.67) | EGFRARPIK3CDPIK3CAFGFR4 | |
| Benzene SCHEMBL28800798 | 0.79 | EGFR (0.65) | EGFRARPIK3CDPIK3CAFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242565-A1 | Macrolides with Modified Desosamine Sugars and Uses Thereof | ZIKANI THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-11673910-B2 | Macrolides with modified desosamine sugars and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-06-13 | — | — | US | disclosed |
| WO-2023086220-A2 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
| EP-4104861-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2022-12-21 | — | — | EP | disclosed |
| US-20220098154-A1 | ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2022-03-31 | — | — | US | disclosed |
| US-11230531-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2022-01-25 | — | — | US | disclosed |
| EP-3917627-A1 | ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | Ideaya Biosciences, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2021141041-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | 大日本住友製薬株式会社 | 2021-07-15 | — | — | WO | disclosed |
| WO-2021039961-A1 | RING-FUSED PYRAZOLE DERIVATIVE | 大日本住友製薬株式会社 | 2021-03-04 | — | — | WO | disclosed |
| US-9242975-B2 | Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242976-B2 | Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| US-8987311-B2 | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-24 | — | — | US | disclosed |
| US-20150045347-A1 | TRIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-02-12 | — | — | US | disclosed |
| US-20150011532-A1 | HETEROCYCLIC-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-08 | — | — | US | disclosed |
| US-7572798-B2 | Prevent Dna damage; antitumor, anticancer agents; blocking epidermal growth factor receptor | MCGILL UNIVERSITY (CA) | 2009-08-11 | — | — | US | disclosed |
| EP-1366027-B1 | COMBI-MOLECULES HAVING SIGNAL TRANSDUCTION INHIBITORY PROPERTIES AND DNA DAMAGING PROPERTIES | UNIV MCGILL (CA) | 2006-09-20 | — | — | EP | disclosed |
| US-20040086907-A1 | Combi-molecules having signal transduction inhibitory properties and dna damaging properties | QIU, QIYU | 2004-05-06 | — | — | US | disclosed |
| EP-1366027-A1 | COMBI-MOLECULES HAVING SIGNAL TRANSDUCTION INHIBITORY PROPERTIES AND DNA DAMAGING PROPERTIES | McGILL UNIVERSITY (CA) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002068396-A1 | COMBI-MOLECULES HAVING SIGNAL TRANSDUCTION INHIBITORY PROPERTIES AND DNA DAMAGING PROPERTIES | MCGILL UNIVERSITY (CA) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098154-A1 | ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | POLQ, POLH, POLB | EGFR 1481/4885AR 1786/4885PIK3CD 122/4885 |
| US-11673910-B2 | Macrolides with modified desosamine sugars and uses thereof | FUT6, DDOST, MGAM | EGFR 3594/4885AR 3770/4885PIK3CD 704/4885 |
| US-20150045347-A1 | TRIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | IRAK4, IRAK3, IRAK1 | EGFR 916/4885AR 2940/4885PIK3CD 122/4885 |
| US-20150011532-A1 | HETEROCYCLIC-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | IRAK4, IRAK1, IRAK2 | EGFR 972/4885AR 2722/4885PIK3CD 283/4885 |
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | MAPT, PSEN1, PSEN2 | EGFR 4765/4885AR 3678/4885PIK3CD 3545/4885 |
| US-20230242565-A1 | Macrolides with Modified Desosamine Sugars and Uses Thereof | FUT6, DDOST, MGAM | EGFR 3594/4885AR 3770/4885PIK3CD 704/4885 |
| US-11230531-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, BRCA1, AHR | EGFR 1577/4885AR 1/4885PIK3CD 2701/4885 |
| US-20040086907-A1 | Combi-molecules having signal transduction inhibitory properties and dna damaging properties | EGFR, PCNA, ERCC2 | EGFR 1/4885AR 2131/4885PIK3CD 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.